SVRA - NASDAQ

Savara Inc.

SVRA·NASDAQ

$5.25

+1.9%

HealthcareBiotechnology

Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases. Its lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase III development stage for the treatment of autoimmune pulmonary alveolar proteinosis. The company is headquartered in Austin, Texas.

Statements Value Model

At a Glance

Live Snapshot

Market Cap$1.08B

EPS-0.5300

P/E Ratio-9.91

Earnings Date08/06/2026

253.44M

Assets

19%

3Y+81.0%

5Y+159.0%

10Y+776.0%

50.30M

Total Liabilities

21%

3Y+57.0%

5Y+51.0%

10Y-22.0%

203.13M

Total Equity

18%

3Y+88.0%

5Y+216.0%

10Y-666.0%

Savara Inc. Funding & Solvency Profile

SVRA · NASDAQ

Current Assets

Cash & Cash Equivalents33.18M

Net Receivables1.25M

Inventory0.00

Other Current Assets1.29M

Total Current Assets242 M

Non-Current Assets

Property, Plant & Equipment100.00K

Goodwill & Intangible Assets11.64M

Long-Term Investments0.00

Other Non-Current Assets84.00K

Total Non-Current Assets184 K

Total Assets

253.44M

Financial Health Analysis

Current Ratio

11.85x

Excellent liquidity position. The company can easily cover its short-term obligations with substantial cushion.

Debt-to-Equity Ratio

0.25x

Conservative capital structure. The company relies primarily on equity financing, indicating low financial risk.

Working Capital

221 M

Strong working capital position provides significant operational flexibility and financial cushion.

Asset Composition

95% Current

Asset-light business model with high liquidity. Majority of assets are easily convertible to cash.

Financial Health Insight

Strong financial foundation: Excellent liquidity combined with conservative leverage suggests the company is well-positioned to weather economic uncertainties and fund growth opportunities.

Savara Inc. Balance Sheet

SVRA • NASDAQ

Savara Inc. Balance Sheet	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019	Dec 2018	Dec 2017	Dec 2016	Dec 2015	Dec 2014	Dec 2013	Dec 2012	Dec 2011	Dec 2010	Dec 2009	Dec 2008	Dec 2007	Dec 2006
ASSETS
CURRENT ASSETS
Cash and Cash Equivalents	33.2M	15.1M	26.6M	52.1M	34M	22.9M	49.8M	24.3M	22.1M	13.4M	23.1M	35.8M	25.7M	22.5M	43.6M	28M	8.7M	9.8M	14.8M	26M
Short-Term Investments	202.5M	181.2M	135.7M	73.8M	127.2M	59.3M	72M	86.5M	72.2M	0.0	17.9M	21.5M	18.7M	14M	7.1M	0.0	0.0	0.0	18.7M	25.8M
Cash & Short-Term Investments	235.7M	196.3M	162.3M	125.9M	161.2M	82.2M	121.8M	110.8M	94.3M	13.4M	41M	57.3M	44.4M	36.5M	50.7M	28M	8.7M	9.8M	33.5M	51.7M
Net Receivables	1.3M	1M	1M	954K	1.1M	1.7M	1.6M	1.7M	1M	868K	0.0	0.0	0.0	15.7K	17.2K	2K	14.8K	121.7K	72K	80.3K
Accounts Receivables	0.0	1M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	400K	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Other Receivables	1.3M	0.0	1M	954K	1.1M	1.7M	1.6M	1.7M	1M	400K	0.0	0.0	0.0	15.7K	17.2K	2K	14.8K	121.7K	72K	80.3K
Inventory	0.0	0.0	0.0	2.1M	-1.1M	0.0	-1.6M	0.0	2.5M	337K	0.0	0.0	0.0	0.0	-831.9K	0.0	0.0	0.0	0.0	0.0
Prepaids	3.4M	4.3M	2.3M	2.1M	2.3M	1.2M	682K	723K	2.5M	278K	67K	1.1M	1.1M	646.6K	256.3K	428.3K	290.2K	477.9K	615.7K	511.3K
Other Current Assets	1.3M	455K	280K	-2M	1.5M	0.0	1.6M	107K	40K	94K	1.3M	0.0	1.1M	0.0	815K	0.0	0.0	0.0	0.0	0.0
Total Current Assets	241.6M	202.1M	165.9M	129M	165M	85.1M	124.1M	113.3M	97.9M	14.6M	42.3M	58.4M	45.5M	37.2M	50.7M	28.4M	9M	10.4M	34.2M	52.3M
NON-CURRENT ASSETS
Property, Plant, and Equipment (Net)	100K	165K	270K	51K	73K	156K	352K	522K	925K	793K	226K	188K	105.7K	198.4K	464.5K	44.3K	44.2K	199.1K	332.4K	403K
Goodwill	0.0	0.0	0.0	0.0	0.0	0.0	0.0	26.9M	27.1M	3.1M	3M	3M	3M	3M	3M	0.0	0.0	0.0	0.0	0.0
Intangible Assets	11.6M	10.3M	11M	10.7M	11.3M	12.2M	11.1M	11.4M	33.6M	10.5M	8.5M	8.5M	6.5M	6.5M	0.0	0.0	0.0	0.0	0.0	0.0
Goodwill & Intangible Assets	11.6M	10.3M	11M	10.7M	11.3M	12.2M	11.1M	38.3M	60.7M	13.5M	11.6M	11.6M	9.6M	9.6M	3M	0.0	0.0	0.0	0.0	0.0
Long-Term Investments	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-3.1M	-465K	-1.1M	-3.4M	-3.4M	-2.6M	-2.6M	-1.5M	0.0	0.0	0.0	0.0	0.0
Tax Assets	0.0	0.0	0.0	0.0	0.0	0.0	0.0	3.1M	465K	995K	3.4M	3.4M	2.6M	2.6M	2.6M	0.0	0.0	0.0	0.0	0.0
Other Non-Current Assets	84K	242K	387K	116K	251K	250K	673K	131K	131K	131K	183K	353K	60.3K	43.9K	6.6M	33.5K	10.5K	60.7K	58.3K	58.3K
Total Non-Current Assets	11.8M	10.7M	11.6M	10.8M	11.6M	12.6M	12.1M	38.9M	61.8M	14.3M	12M	12.1M	9.7M	9.8M	11.2M	77.7K	54.7K	259.7K	390.7K	461.3K
Total Assets	253.4M	212.9M	177.6M	139.8M	176.6M	97.7M	136.2M	152.3M	159.6M	28.9M	54.2M	70.5M	55.2M	47M	61.9M	28.5M	9M	10.7M	34.5M	52.8M
LIABILITIES
CURRENT LIABILITIES
Total Payables	5.8M	4.5M	3.5M	1.3M	1.4M	2.6M	3.4M	3.9M	2.8M	536K	2.6M	1.4M	963.9K	698.8K	451.7K	479.8K	385.4K	1.7M	552.1K	480.4K
Accounts Payable	5.8M	4.5M	3.5M	1.3M	1.4M	2.6M	3.4M	3.9M	2.8M	536K	2.6M	1.4M	963.9K	698.8K	451.7K	479.8K	385.4K	1.7M	552.1K	480.4K
Accrued Expenses	6.6M	5M	2.9M	4.5M	4.7M	3.5M	5M	643K	1.6M	2.4M	1.4M	5.6M	1.4M	445.4K	756.8K	456.8K	2M	3M	2.9M	292.9K
Short Term Debt	7K	0.0	0.0	0.0	8.3M	0.0	2M	41K	265K	0.0	11M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Capital Lease Obligations (Current)	0.0	116K	143K	64K	135K	179K	440K	41K	265K	442K	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Deferred Revenue	0.0	0.0	0.0	0.0	0.0	0.0	0.0	250K	3M	2.2M	9.3M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Other Current Liabilities	8.1M	5M	4M	0.0	0.0	1.9M	0.0	2.4M	1.1M	47K	8.2M	1.4M	2.5M	1.4M	1.3M	864.9K	0.0	0.0	0.0	32M
Total Current Liabilities	20.4M	14.7M	10.6M	5.9M	14.7M	8.2M	10.9M	7.3M	6M	3.5M	23.2M	8.4M	4.8M	2.6M	2.5M	1.8M	2.4M	4.7M	3.5M	32.8M
NON-CURRENT LIABILITIES
Long Term Debt	29.9M	26.6M	26.3M	26.1M	17.3M	25.1M	23.1M	24.5M	14.8M	3.4M	3.7M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Deferred Revenue (Non-Current)	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-3.1M	0.0	45.3M	-25K	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Deferred Tax Liabilities (Non-Current)	0.0	0.0	0.0	0.0	0.0	0.0	0.0	3.1M	7.2M	2.3M	3.4M	3.4M	2.6M	2.6M	2.6M	0.0	0.0	0.0	0.0	0.0
Other Non-Current Liabilities	0.0	87K	247K	54K	117K	84K	513K	12.3M	12.1M	55M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	14.3K	35.7K
Total Non-Current Liabilities	29.9M	26.7M	26.6M	26.1M	17.4M	25.2M	23.6M	36.8M	34.3M	61.4M	7.2M	3.4M	2.6M	2.6M	2.6M	0.0	0.0	0.0	14.3K	35.7K
Other Liabilities	0.0	0.0	0.0	0.0	0.0	0.0	0.0	108.2M	0.0	0.0	0.0	0.0	0.0	0.0	-774.0	0.0	0.0	0.0	0.0	0.0
Capital Lease Obligations	0.0	116K	143K	64K	135K	179K	440K	41K	562K	1M	25K	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Total Liabilities	50.3M	41.4M	37.2M	32M	32.1M	33.4M	34.5M	152.3M	40.3M	64.8M	30.3M	11.8M	7.4M	5.2M	5.1M	1.8M	2.4M	4.7M	3.5M	32.8M
SHAREHOLDERS' EQUITY
Treasury Stock	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-1.5K	0.0	0.0	0.0	0.0	0.0	0.0
Preferred Stock	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	159.6M	43.9M	43.3K	0.0	0.0	0.0	303.0	0.0	0.0	0.0	0.0	0.0
Common Stock	204K	173K	140K	116K	116K	55K	52K	36K	32K	5K	164K	159K	102.7K	47.7K	47.7K	15.5K	205.3K	90.3K	90.3K	89.7K
Additional Paid-In Capital	811.1M	661.3M	533.9M	446.9M	444.9M	320.9M	309.6M	237.7M	186.5M	3.1M	298.7M	293.7M	254.2M	226.7M	226.1M	182.8M	148.5M	131.8M	130.1M	109.2M
Retained Earnings	-608.1M	-489.3M	-393.4M	-338.7M	-300.5M	-257.5M	-207.9M	-129.7M	-68.2M	-38.4M	-275M	-235.1M	-206.4M	-184.9M	-169.4M	-156.1M	-142M	-125.8M	-99.2M	-89.3M
Accumulated Other Comprehensive Income/Loss	-87K	-750K	-271K	-605K	5K	942K	-17K	200K	958K	-591K	-17K	-25K	-20.7K	-2.2K	-2.3K	-255K	-338.7K	0.0	2.7K	-2.1K
Other Total Stockholders' Equity	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-44.2M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Total Stockholders' Equity	203.1M	171.4M	140.4M	107.8M	144.5M	64.4M	101.7M	108.2M	119.3M	-35.9M	23.9M	58.7M	47.8M	41.8M	56.8M	26.7M	6.7M	6M	31M	20M
Total Equity	203.1M	171.4M	140.4M	107.8M	144.5M	64.4M	101.7M	108.2M	119.3M	-35.9M	23.9M	58.7M	47.8M	41.8M	56.8M	26.7M	6.7M	6M	31M	20M
SUMMARY
Total Liabilities & Equity	253.4M	212.9M	177.6M	139.8M	176.6M	97.7M	136.2M	152.3M	159.6M	28.9M	54.2M	70.5M	55.2M	47M	61.9M	28.5M	9M	10.7M	34.5M	52.8M
Total Investments	202.5M	181.2M	135.7M	73.8M	127.2M	59.3M	72M	83.4M	72.2M	-1.1M	14.5M	18.1M	18.7M	11.4M	7.1M	0.0	0.0	0.0	18.7M	25.8M
Total Debt	29.9M	26.7M	26.5M	26.1M	25.8M	25.3M	25.6M	24.6M	15.3M	4.5M	14.7M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Net Debt	-3.3M	11.6M	-94K	-26M	-8.2M	2.4M	-24.3M	270K	-6.8M	-8.9M	-8.3M	-35.8M	-25.7M	-22.5M	-43.6M	-28M	-8.7M	-9.8M	-14.8M	-26M
Shares Outstanding	196,659,967	196,659,967	196,659,967	196,659,967	196,659,967	196,659,967	196,659,967	196,659,967	196,659,967	196,659,967	196,659,967	196,659,967	196,659,967	196,659,967	196,659,967	196,659,967	196,659,967	196,659,967	196,659,967	196,659,967

SEC Filings

SVRA - Filing history and reports

Filing Type	Filing Date	Period Ending	Fiscal Year	Actions
8-K 8-K 2026 N/A	January 27, 2026	January 26, 2026	2026	View Filing
8-K 8-K 2026 N/A	January 09, 2026	January 09, 2026	2026	View Filing
10-Q 10-Q 2025 Q3 Q3	November 12, 2025	September 30, 2025	2025	View Filing
8-K 8-K 2025 N/A	October 30, 2025	October 29, 2025	2025	View Filing
8-K 8-K 2025 N/A	October 29, 2025	October 29, 2025	2025	View Filing
8-K 8-K 2025 N/A	September 02, 2025	September 02, 2025	2025	View Filing
10-Q 10-Q 2025 Q2 Q2	August 13, 2025	June 30, 2025	2025	View Filing
8-K 8-K 2025 N/A	June 06, 2025	June 05, 2025	2025	View Filing
8-K 8-K 2025 N/A	May 27, 2025	May 27, 2025	2025	View Filing
10-Q 10-Q 2025 Q1 Q1	May 13, 2025	March 31, 2025	2025	View Filing

Showing 1 to 10 of 537 filings

Related Guides

Blog Categories

Continue your SVRA research with focused valuation guides.

Fundamentals

Decode statement quality and operating durability.

Accounting

Interpret line items with cleaner analytical framing.

Forecasting

Translate historical performance into forward scenarios.

Reference

Use practical frameworks for statement-led valuation.

Research Paths

Pick your next lens

Snapshot

Start with context, operating signals, and key market metrics.

Value Model

Stress test fair value across bear, base, and bull assumptions.

Statements

Validate revenue quality, margins, and balance sheet durability.

Earnings Call

Read management commentary and compare it with reported outcomes.

Dividends

Check payout sustainability and long-term distribution behavior.

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.